From the Desk of Evan Yu: “PARP with PD-1/PD-L1 inhibition. Is there any magic to the combination in a molecularly unselected patient population?”
Previously, I’ve written Clinical Trials Portal articles about the concept of PARP inhibition in men with prostate cancer, with a strong focus on the biologic selection of patients with homologous recombination deficiency as most likely candidates for response to such agents.1,2 About 1.5 years ago, I wrote an article highlighting ongoing PD-1/PD-L1 antibody combination trials in prostate cancer.3 At that time, the goal was to consider intelligent combinations with immune-oncology agents in what has essentially been considered an immune “cold” prostate tumor microenvironment. Hence, multiple trial partners in combination with PD-1/PD-L1 antibodies were proposed and referenced at that time.
Evan Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Professor, Department of Medical Oncology, University of Washington School of Medicine
- Member, Fred Hutchinson Cancer Research Center
- Assistant Fellowship Director, Hematology and Oncology Fellowship Training Program, University of Washington and Fred Hutchinson Cancer Research Center.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.